Սինգապուր -
անգլերեն -
HSA (Health Sciences Authority)
fraxiparine injection 1900 iu axa0.2 ml
dch auriga singapore - nadroparin calcium - injection - nadroparin calcium 1900 iu axa/0.2 ml
Սինգապուր -
անգլերեն -
HSA (Health Sciences Authority)
fraxiparine injection 7600 iu axa0.8 ml
dch auriga singapore - nadroparin calcium - injection - nadroparin calcium 7600 iu axa/0.8 ml
Սինգապուր -
անգլերեն -
HSA (Health Sciences Authority)
fraxiparine injection 9500 iu axa1.0 ml
dch auriga singapore - nadroparin calcium - injection - nadroparin calcium 9500 iu axa/1.0 ml
Նամիբիա -
անգլերեն -
Namibia Medicines Regulatory Council
fraxiparine 1,0 ml
aventis pharma (pty) limited - nadroparin calcium - injection - each 1,0 ml of solution contains nadroparin calcium 9500 iu axa
Նամիբիա -
անգլերեն -
Namibia Medicines Regulatory Council
fraxiparine 0,3 ml
aventis pharma (pty) limited - nadroparin calcium - injection - each 0,3 ml of solution contains nadroparin calcium 2850 iu axa
Նամիբիա -
անգլերեն -
Namibia Medicines Regulatory Council
fraxiparine 0,2 ml
pharmacare limited - nadroparin calcium - injection - each 0,2 ml of solution contains nadroparin calcium 1900 iu axa
Նամիբիա -
անգլերեն -
Namibia Medicines Regulatory Council
fraxiparine 0,4 ml
pharmacare limited - nadroparin calcium - injection - each 0,4 ml of solution contains nadroparin calcium 3800 iu axa
Նամիբիա -
անգլերեն -
Namibia Medicines Regulatory Council
fraxiparine 0,6 ml
pharmacare limited - nadroparin calcium - injection - each 0,6 ml of solution contains nadroparin calcium 5700 iu axa
Նամիբիա -
անգլերեն -
Namibia Medicines Regulatory Council
fraxiparine 0,8 ml
pharmacare limited - nadroparin calcium - injection - each 0,8 ml of solution contains nadroparin calcium 7600 iu axa
Իսրայել -
անգլերեն -
Ministry of Health
fraxiparine 3800 iu axa/ 0.4 ml
glaxo smith kline (israel) ltd - nadroparin calcium 3800 iu / 0.4 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during heamodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.